So now that B-UP has had an amazingly successful trial result and we know B-OM's interim result was unbelievably good and B-ABSSSI did better than the SOC with a single dose, does IPIX try to sell/partner the entire platform? I know IPIX has stated that they do not plan to take these indications to PIII and commercialization alone, so are we at that point where it makes sense? I could see them setting up a deal that includes these first three indications with other indications as milestones to be met further down the road. I don't recall a serious mention of initiating other trials for B, so is it possible this could be it (assuming B-OM finishes relatively soon) and BP is already lined up to sign on the dotted line?